Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BV601 HPV Vaccine in Healthy Adults
NCT05672966Phase 1Unknown
- Sponsor
- Wuhan BravoVax Co., Ltd
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BV601 in human papillomavirus infection (6 arms), sponsored by Wuhan BravoVax Co., Ltd. Primary endpoints: Safety in terms of solicited adverse events, Safety in terms of solicited systemic AEs and 3 more. Status: unknown.
02
Drugs
BV601
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05672966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672966.